Pembrolizumab versus Ipilimumab in Advanced Melanoma.

@article{Robert2015PembrolizumabVI,
  title={Pembrolizumab versus Ipilimumab in Advanced Melanoma.},
  author={C Melville Robert and Jacob M Schachter and Georgina V. Long and Ana M Arance and Jean Jacques Grob and Laurent Mortier and Adil I Daud and Matteo Carlino and Catriona Mcneil and Michal Lotem and James Larkin and Paul C. Lorigan and Bart Neyns and Christian U Blank and Omid A. Hamid and Christine Mateus and Ronnie Shapira-Frommer and M Caroline Kosh and Honghong Zhou and Nageatte Ibrahim and Scot W. Ebbinghaus and Antoni Ribas},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 26},
  pages={
          2521-32
        }
}
BACKGROUND The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 1,253 CITATIONS

Immune checkpoint inhibitors: therapeutic advances in melanoma.

  • Annals of translational medicine
  • 2015
VIEW 19 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 63 Highly Influenced Citations

  • Averaged 367 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. Presented at the Society for Melanoma

A Ribas, I Puzanov, R Drummer
  • Research 2014 International Congress,
  • 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014

Similar Papers

Loading similar papers…